RxDoctor Payments Data

Hugo Toro, MD

Internal Medicine · Katy, TXNPI 1861495541

Payments from drug & device makers

$320,879in general payments, 2019–2025

Across 206 payments — averaging $1557.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$164K
  • Novo Nordisk AS$115K
  • Lexicon Pharmaceuticals, Inc.$33K
  • Esperion Therapeutics, Inc.$4K
  • Kowa Research Institute, Inc.$3K
  • Abbott$210
  • plus $213 from 4 others

What the payments were for

  • Food & beverage$32878%
  • Education$9522%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$320,879 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$76,165
Medicare patients
211
Services billed
732

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin222$283,448
FarxigaDapagliflozin Propanediol234$258,495
JanuviaSitagliptin Phosphate159$202,300
OzempicSemaglutide152$181,242
Tresiba Flextouch U-100Insulin Degludec103$112,478
EliquisApixaban101$89,671
TradjentaLinagliptin44$55,949
RybelsusSemaglutide25$49,888
TrulicityDulaglutide47$48,812
MyrbetriqMirabegron41$44,639
LinzessLinaclotide38$43,795
XareltoRivaroxaban37$38,302
DovatoDolutegravir Sodium/Lamivudine11$37,901
MounjaroTirzepatide29$34,344
Janumet XrSitagliptin Phos/Metformin Hcl28$34,326

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$95$44,63941 claims
AbbVieLinzess$32$43,79538 claims
Johnson & JohnsonXarelto$66$38,30237 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Katy

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →